The pharmacologic inhibition of the xc- antioxidant system improves the antitumor efficacy of COX inhibitors in the in vivo model of 3-MCA tumorigenesis.
暂无分享,去创建一个
[1] P. Kalinski. Regulation of Immune Responses by Prostaglandin E2 , 2012, The Journal of Immunology.
[2] M. Netea,et al. Interplay between redox status and inflammasome activation. , 2011, Trends in immunology.
[3] M. Karin,et al. Tumor promotion via injury- and death-induced inflammation. , 2011, Immunity.
[4] M. Ciriolo,et al. The cystine/cysteine cycle and GSH are independent and crucial antioxidant systems in malignant melanoma cells and represent druggable targets. , 2011, Antioxidants & redox signaling.
[5] A. Castiglioni,et al. High-mobility group box 1 release and redox regulation accompany regeneration and remodeling of skeletal muscle. , 2011, Antioxidants & redox signaling.
[6] Scott E. Kern,et al. Oncogene-induced Nrf2 transcription promotes ROS detoxification and tumorigenesis , 2011, Nature.
[7] M. Cantwell,et al. A systematic review to establish the frequency of cyclooxygenase-2 expression in normal breast epithelium, ductal carcinoma in situ, microinvasive carcinoma of the breast and invasive breast cancer , 2011, British Journal of Cancer.
[8] P. Castellani,et al. CIITA‐driven MHC‐II positive tumor cells: Preventive vaccines and superior generators of antitumor CD4+ T lymphocytes for immunotherapy , 2010, International journal of cancer.
[9] R. Sitia,et al. Redox remodeling allows and controls B-cell activation and differentiation. , 2010, Antioxidants & redox signaling.
[10] C. Low,et al. Potential use of the anti-inflammatory drug, sulfasalazine, for targeted therapy of pancreatic cancer. , 2010, Current oncology.
[11] S. Wakana,et al. xCT deficiency accelerates chemically induced tumorigenesis , 2010, Proceedings of the National Academy of Sciences.
[12] A. Rubartelli,et al. DAMPs and inflammatory processes: the role of redox in the different outcomes , 2009, Journal of leukocyte biology.
[13] E. Podack,et al. A critical analysis of the tumour immunosurveillance controversy for 3-MCA-induced sarcomas , 2009, British Journal of Cancer.
[14] M. Ciriolo,et al. Pathogen-Induced Interleukin-1β Processing and Secretion Is Regulated by a Biphasic Redox Response1 , 2009, The Journal of Immunology.
[15] H. Sontheimer,et al. Sulfasalazine inhibits the growth of primary brain tumors independent of nuclear factor‐κB , 2009, Journal of neurochemistry.
[16] J. Estrela,et al. Oxidative stress in environmental-induced carcinogenesis. , 2009, Mutation research.
[17] Srinivas Nagaraj,et al. Myeloid-derived suppressor cells as regulators of the immune system , 2009, Nature Reviews Immunology.
[18] S. Ferrini,et al. The redox state of the lung cancer microenvironment depends on the levels of thioredoxin expressed by tumor cells and affects tumor progression and response to prooxidants , 2008, International journal of cancer.
[19] Michelle Collazo,et al. Subsets of Myeloid-Derived Suppressor Cells in Tumor-Bearing Mice1 , 2008, The Journal of Immunology.
[20] A. Rubartelli,et al. The thiol redox state of lymphoid organs is modified by immunization: Role of different immune cell populations , 2008, European journal of immunology.
[21] Yuzhuo Wang,et al. The xc− cystine/glutamate antiporter: a mediator of pancreatic cancer growth with a role in drug resistance , 2008, British Journal of Cancer.
[22] P. Allavena,et al. Cancer-related inflammation , 2008, Nature.
[23] A. Vickers,et al. Should supplemental antioxidant administration be avoided during chemotherapy and radiation therapy? , 2008, Journal of the National Cancer Institute.
[24] V. Bronte,et al. Tumor‐induced tolerance and immune suppression by myeloid derived suppressor cells , 2008, Immunological reviews.
[25] S. Akira,et al. Demonstration of inflammation-induced cancer and cancer immunoediting during primary tumorigenesis , 2008, Proceedings of the National Academy of Sciences.
[26] G. Wondrak,et al. Experimental therapeutics: targeting the redox Achilles heel of cancer. , 2007, Current opinion in investigational drugs.
[27] J. Talmadge. Pathways Mediating the Expansion and Immunosuppressive Activity of Myeloid-Derived Suppressor Cells and Their Relevance to Cancer Therapy , 2007, Clinical Cancer Research.
[28] D. Nie,et al. Cyclooxygenases, prostanoids, and tumor progression , 2007, Cancer and Metastasis Reviews.
[29] A. Holmgren,et al. Targeting thioredoxin reductase is a basis for cancer therapy by arsenic trioxide , 2007, Proceedings of the National Academy of Sciences.
[30] Wan-Wan Lin,et al. A cytokine-mediated link between innate immunity, inflammation, and cancer. , 2007, The Journal of clinical investigation.
[31] Yoichiro Iwakura,et al. Interleukin-1beta-driven inflammation promotes the development and invasiveness of chemical carcinogen-induced tumors. , 2007, Cancer research.
[32] A. Buckley,et al. Sulfasalazine‐induced cystine starvation: Potential use for prostate cancer therapy , 2007, The Prostate.
[33] R. Issels,et al. The cystine/cysteine cycle: a redox cycle regulating susceptibility versus resistance to cell death , 2006, Oncogene.
[34] Alberto Mantovani,et al. Tumour-associated macrophages are a distinct M2 polarised population promoting tumour progression: potential targets of anti-cancer therapy. , 2006, European journal of cancer.
[35] Paolo Serafini,et al. Myeloid suppressor cells in cancer: recruitment, phenotype, properties, and mechanisms of immune suppression. , 2006, Seminars in cancer biology.
[36] Jeannette Bigler,et al. Non-steroidal anti-inflammatory drugs for cancer prevention: promise, perils and pharmacogenetics , 2006, Nature Reviews Cancer.
[37] Ying Huang,et al. Cystine-glutamate transporter SLC7A11 in cancer chemosensitivity and chemoresistance. , 2005, Cancer research.
[38] R. DuBois,et al. COX-2: a molecular target for colorectal cancer prevention. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[39] Hans Clevers,et al. At the Crossroads of Inflammation and Cancer , 2004, Cell.
[40] Michael T. Lotze,et al. Inflammation and necrosis promote tumour growth , 2004, Nature Reviews Immunology.
[41] C. Harris,et al. Radical causes of cancer , 2003, Nature Reviews Cancer.
[42] G. Filomeni,et al. Antigen-presenting dendritic cells provide the reducing extracellular microenvironment required for T lymphocyte activation , 2002, Proceedings of the National Academy of Sciences of the United States of America.
[43] N. Bruchovsky,et al. Sulfasalazine, a potent suppressor of lymphoma growth by inhibition of the xc− cystine transporter: a new action for an old drug , 2001, Leukemia.
[44] A. Holmgren,et al. Widespread expression of thioredoxin and thioredoxin reductase in non-small cell lung carcinoma. , 2001, Clinical cancer research : an official journal of the American Association for Cancer Research.
[45] R. Schreiber,et al. IFNγ and lymphocytes prevent primary tumour development and shape tumour immunogenicity , 2001, Nature.
[46] L. G. García Rodríguez,et al. Reduced Risk of Colorectal Cancer among Long-Term Users of Aspirin and Nonaspirin Nonsteroidal Antiinflammatory Drugs , 2001, Epidemiology.
[47] E. Giovannucci. The prevention of colorectal cancer by aspirin use. , 1999, Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie.
[48] R. Schreiber,et al. Demonstration of an interferon γ-dependent tumor surveillance system in immunocompetent mice , 1998 .
[49] C. Fletcher,et al. Soft Tissue Tumors , 1995, Current Topics in Pathology.
[50] N. Bruchovsky,et al. Increased cystine uptake capability associated with malignant progression of Nb2 lymphoma cells , 1997, Leukemia.
[51] R. White,et al. Prostaglandin H synthase 2 is expressed abnormally in human colon cancer: evidence for a transcriptional effect. , 1996, Proceedings of the National Academy of Sciences of the United States of America.
[52] R. Cawson. Soft tissue tumors, 3rd edition, 1995: F.M. Enzinger and S.W. Weiss. Mosby, St Louis, £160 , 1995 .
[53] R. Coffey,et al. Up-regulation of cyclooxygenase 2 gene expression in human colorectal adenomas and adenocarcinomas. , 1994, Gastroenterology.
[54] F. Enzinger,et al. Soft tissue tumors , 1988 .
[55] P. Cerutti. Prooxidant states and tumor promotion. , 1985, Science.
[56] Hideyo Sato,et al. The oxidative stress-inducible cystine/glutamate antiporter, system xc−: cystine supplier and beyond , 2011, Amino Acids.
[57] P. Sinha,et al. Myeloid-derived suppressor cells inhibit T-cell activation by depleting cystine and cysteine. , 2010, Cancer research.
[58] J. Baron,et al. Nonsteroidal anti-inflammatory drugs and cancer prevention. , 2000, Annual review of medicine.
[59] R. Schreiber,et al. Demonstration of an interferon gamma-dependent tumor surveillance system in immunocompetent mice. , 1998, Proceedings of the National Academy of Sciences of the United States of America.